Adding Palbociclib to Targeted and Endocrine Therapy in Triple-Positive Breast Cancer
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 11th, 2026
|
Breast cancers that express estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 offer multiple therapeutic targets. This subtype, often referred to as triple-positive breast cancer, is typically managed with a combination of HER2-directed agents and endocrine therapy. However, treatment resistance remains a major challenge. Because dysregulation of the cell cycle contributes to tumor growth and progression, a study was conducted to evaluate whether adding the CDK4/6 inhibitor palbociclib could improve outcomes in this patient population.
Funding Source(s): Pfizer
The phase 3 clinical trial enrolled 518 participants, including two men, with a median age of 53.4 years. At baseline, 73.6% of patients had visceral metastases, 3.9% had central nervous system involvement, and 22.6% had nonvisceral metastatic disease. Among female participants, 61.8% were postmenopausal and the remainder were premenopausal. Tumor profiling showed estrogen receptor expression in 97.5% of cases, while 69.3% also expressed progesterone receptors.
All participants received standard anti-HER2 and endocrine therapy and were randomly assigned to either receive additional oral palbociclib or continue standard treatment alone. Palbociclib was administered at 125 mg once daily for 21 consecutive days, followed by a 7-day break. The drug exerts its antitumor effect by inhibiting cyclin D-CDK4/6 complexes, thereby preventing cell-cycle progression and limiting tumor cell proliferation.
After a median follow-up of 53.5 months, patients treated with palbociclib demonstrated a significantly longer median progression-free survival of 44.3 months, compared with 29.1 months in the control group. Overall, the addition of palbociclib reduced the risk of disease progression or death by approximately 25%. Despite these benefits, clinicians should carefully monitor for adverse effects, as palbociclib was associated with higher rates of neutropenia, leukopenia, anemia, diarrhea, and other treatment-related toxicities.
Funding Source(s): Pfizer
The phase 3 clinical trial enrolled 518 participants, including two men, with a median age of 53.4 years. At baseline, 73.6% of patients had visceral metastases, 3.9% had central nervous system involvement, and 22.6% had nonvisceral metastatic disease. Among female participants, 61.8% were postmenopausal and the remainder were premenopausal. Tumor profiling showed estrogen receptor expression in 97.5% of cases, while 69.3% also expressed progesterone receptors.
All participants received standard anti-HER2 and endocrine therapy and were randomly assigned to either receive additional oral palbociclib or continue standard treatment alone. Palbociclib was administered at 125 mg once daily for 21 consecutive days, followed by a 7-day break. The drug exerts its antitumor effect by inhibiting cyclin D-CDK4/6 complexes, thereby preventing cell-cycle progression and limiting tumor cell proliferation.
After a median follow-up of 53.5 months, patients treated with palbociclib demonstrated a significantly longer median progression-free survival of 44.3 months, compared with 29.1 months in the control group. Overall, the addition of palbociclib reduced the risk of disease progression or death by approximately 25%. Despite these benefits, clinicians should carefully monitor for adverse effects, as palbociclib was associated with higher rates of neutropenia, leukopenia, anemia, diarrhea, and other treatment-related toxicities.